https://de.marketscreener.com/kurs/aktie/DAIICHI-SANKYO-CO-LTD-6498062/news/Biologics-License-Application-fur-Datopotamab-Deruxtecan-in-den-USA-fur-Patienten-mit-vorbehandelt-46337870/?utm_source=telegram&utm_medium=social&utm_campaign=share